Form 4: Agios CEO Brian Goff Executes Stock Vesting and Sale

Agios Pharmaceuticals CEO Brian Goff acquired shares through performance unit vesting and sold a portion to cover tax obligations.

Summary

• CEO Brian Goff acquired a total of 39,028 shares of common stock on April 2, 2026, through the vesting of performance share units (PSUs).
• A total of 19,068 shares were sold at a price of $34.71 per share to satisfy mandatory tax withholding obligations.
• The transactions were executed under pre-existing Rule 10b5-1(c) trading plans.
• Following these transactions, Brian Goff maintains a direct beneficial ownership of 184,508 shares of Agios common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event; while the sale reduces the CEO's holdings, it is a routine, pre-planned transaction triggered by the successful achievement of company regulatory milestones.

Positives

• Vesting of performance share units indicates the successful achievement of specific regulatory milestones by the company.
• The stock sales were non-discretionary, executed solely to cover tax liabilities associated with the vesting event.

Negatives

• The transaction results in a reduction of the CEO's total share count compared to the immediate post-vesting balance.

Risks

• Future vesting of remaining performance share units is contingent upon achieving additional clinical and commercial milestones.

Future Outlook

The company continues to work toward additional clinical and commercial milestones required for the vesting of the remaining 40,500 performance share units held by the CEO.

Management Comments

• The transactions were effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that the achievement of regulatory milestones is a critical value driver for mid-cap biotechnology firms, often serving as a catalyst for stock price appreciation and long-term institutional interest.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for tax-related sales is standard corporate governance practice for executives in the biotechnology sector to avoid potential insider trading concerns.
• Vesting schedules tied to regulatory and commercial milestones are consistent with industry-standard executive compensation structures designed to align management incentives with shareholder value creation.

Stakeholder Impact

• Shareholders should view the milestone achievement as a positive indicator of operational progress.

Next Steps

• Achievement of remaining clinical and commercial milestones to trigger further PSU vesting.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, Insider Trading, Form 4, Performance Share Units, Executive Compensation, Biotech